The NK1 receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma
What is already known about this subject: Nausea and vomiting are the most distressing side-effects of a high dose melphalan regimen. Aprepitant in addition to an antiemetic standard regimen has been reported to improve significantly both acute and delayed chemotherapy-induced nausea and vomiting. -...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
30 August 2010
|
| In: |
British journal of clinical pharmacology
Year: 2010, Jahrgang: 70, Heft: 6, Pages: 903-907 |
| ISSN: | 1365-2125 |
| DOI: | 10.1111/j.1365-2125.2010.03792.x |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1111/j.1365-2125.2010.03792.x Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2125.2010.03792.x 
|
| Verfasserangaben: | Gerlinde Egerer, Kathrin Eisenlohr, Martina Gronkowski, Juergen Burhenne, Klaus-Dieter Riedel & Gerd Mikus |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1837923566 | ||
| 003 | DE-627 | ||
| 005 | 20230710154613.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230302s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/j.1365-2125.2010.03792.x |2 doi | |
| 035 | |a (DE-627)1837923566 | ||
| 035 | |a (DE-599)KXP1837923566 | ||
| 035 | |a (OCoLC)1389821455 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Egerer, Gerlinde |e VerfasserIn |0 (DE-588)105502168X |0 (DE-627)792516745 |0 (DE-576)167430882 |4 aut | |
| 245 | 1 | 4 | |a The NK1 receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma |c Gerlinde Egerer, Kathrin Eisenlohr, Martina Gronkowski, Juergen Burhenne, Klaus-Dieter Riedel & Gerd Mikus |
| 246 | 3 | 3 | |a The NK 1 receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma |
| 264 | 1 | |c 30 August 2010 | |
| 300 | |a 5 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Im Titel ist die Ziffer 1 bei "NK1" tiefgestellt | ||
| 500 | |a Gesehen am 02.03.2023 | ||
| 520 | |a What is already known about this subject: Nausea and vomiting are the most distressing side-effects of a high dose melphalan regimen. Aprepitant in addition to an antiemetic standard regimen has been reported to improve significantly both acute and delayed chemotherapy-induced nausea and vomiting. - What this study adds: Anti-emetic regimens including aprepitant have no clinically relevant effect on the pharmacokinetics of the anticancer agent melphalan when administered 1 h before high dose melphalan infusion. - Aims: The objective of this investigation was to assess the effect of aprepitant on the pharmacokinetics of high-dose melphalan used as conditioning therapy before blood stem cell transplantation in multiple myeloma. - Methods: Aprepitant (125 mg) or placebo was administered 1 h before melphalan therapy (1 h infusion of 100 mg m−2). Eleven plasma samples were obtained over 8 h and melphalan was quantified using an LC/MS/MS method. Standard pharmacokinetic parameters were calculated and nonparametric testing was applied to assess the differences between aprepitant and placebo treatment. - Results: Twenty patients received placebo and 10 patients aprepitant treatment. There were no differences observed for Cmax at the end of melphalan infusion (placebo 3431 ± 608 ng ml−1vs. aprepitant 3269 ± 660 ng ml−1). In addition, AUC and terminal elimination half-life were not changed by aprepitant. Total clearance of melphalan was 304 ± 58 ml min−1 m−2 (placebo) which was not influenced by aprepitant (288 ± 78 ml min−1 m−2). - Conclusions: The administration of the NK1 receptor antagonist aprepitant 1 h before a high-dose chemotherapy does not influence the exposure and the elimination of melphalan. Therefore, oral administration of 125 mg aprepitant 1 h before melphalan infusion does not alter the disposition of intravenously administered melphalan. | ||
| 650 | 4 | |a aprepitant | |
| 650 | 4 | |a interaction | |
| 650 | 4 | |a melphalan | |
| 700 | 1 | |a Eisenlohr, Kathrin |d 1984- |e VerfasserIn |0 (DE-588)1019561130 |0 (DE-627)685493067 |0 (DE-576)35832730X |4 aut | |
| 700 | 1 | |a Gronkowski, Martina |e VerfasserIn |0 (DE-588)1082256978 |0 (DE-627)847261433 |0 (DE-576)455293198 |4 aut | |
| 700 | 1 | |a Burhenne, Jürgen |d 1963- |e VerfasserIn |0 (DE-588)1034228889 |0 (DE-627)745126987 |0 (DE-576)381858197 |4 aut | |
| 700 | 1 | |a Riedel, Klaus-Dieter |e VerfasserIn |0 (DE-588)1034229605 |0 (DE-627)745128432 |0 (DE-576)381859460 |4 aut | |
| 700 | 1 | |a Mikus, Gerd |e VerfasserIn |0 (DE-588)110903137 |0 (DE-627)691097941 |0 (DE-576)336988710 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of clinical pharmacology |d Oxford : Wiley-Blackwell, 1974 |g 70(2010), 6 vom: Dez., Seite 903-907 |h Online-Ressource |w (DE-627)306585995 |w (DE-600)1498142-7 |w (DE-576)091140056 |x 1365-2125 |7 nnas |a The NK1 receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma |
| 773 | 1 | 8 | |g volume:70 |g year:2010 |g number:6 |g month:12 |g pages:903-907 |g extent:5 |a The NK1 receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma |
| 856 | 4 | 0 | |u https://doi.org/10.1111/j.1365-2125.2010.03792.x |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2125.2010.03792.x |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230302 | ||
| 993 | |a Article | ||
| 994 | |a 2010 | ||
| 998 | |g 110903137 |a Mikus, Gerd |m 110903137:Mikus, Gerd |d 910000 |d 910100 |d 50000 |e 910000PM110903137 |e 910100PM110903137 |e 50000PM110903137 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 6 |y j | ||
| 998 | |g 1034229605 |a Riedel, Klaus-Dieter |m 1034229605:Riedel, Klaus-Dieter |d 910000 |d 910100 |e 910000PR1034229605 |e 910100PR1034229605 |k 0/910000/ |k 1/910000/910100/ |p 5 | ||
| 998 | |g 1034228889 |a Burhenne, Jürgen |m 1034228889:Burhenne, Jürgen |d 910000 |d 910100 |e 910000PB1034228889 |e 910100PB1034228889 |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 998 | |g 1082256978 |a Gronkowski, Martina |m 1082256978:Gronkowski, Martina |d 910000 |d 910100 |e 910000PG1082256978 |e 910100PG1082256978 |k 0/910000/ |k 1/910000/910100/ |p 3 | ||
| 998 | |g 1019561130 |a Eisenlohr, Kathrin |m 1019561130:Eisenlohr, Kathrin |d 50000 |e 50000PE1019561130 |k 0/50000/ |p 2 | ||
| 998 | |g 105502168X |a Egerer, Gerlinde |m 105502168X:Egerer, Gerlinde |d 910000 |d 910100 |e 910000PE105502168X |e 910100PE105502168X |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1837923566 |e 4282445572 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"title":[{"title":"The NK1 receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma","title_sort":"NK1 receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma"}],"note":["Im Titel ist die Ziffer 1 bei \"NK1\" tiefgestellt","Gesehen am 02.03.2023"],"relHost":[{"disp":"The NK1 receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myelomaBritish journal of clinical pharmacology","physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["306585995"],"issn":["1365-2125"],"zdb":["1498142-7"],"doi":["10.1111/(ISSN)1365-2125"]},"note":["Gesehen am 20.03.2014"],"type":{"bibl":"periodical","media":"Online-Ressource"},"titleAlt":[{"title":"BJCP"}],"origin":[{"dateIssuedKey":"1974","dateIssuedDisp":"1974-","publisher":"Wiley-Blackwell ; Blackwell Science ; Blackwell","publisherPlace":"Oxford ; Oxford ; Oxford [u.a.]"}],"recId":"306585995","pubHistory":["1.1974 -"],"title":[{"title_sort":"British journal of clinical pharmacology","title":"British journal of clinical pharmacology","subtitle":"BJCP"}],"part":{"volume":"70","text":"70(2010), 6 vom: Dez., Seite 903-907","year":"2010","pages":"903-907","extent":"5","issue":"6"},"language":["eng"]}],"id":{"doi":["10.1111/j.1365-2125.2010.03792.x"],"eki":["1837923566"]},"physDesc":[{"extent":"5 S."}],"recId":"1837923566","origin":[{"dateIssuedDisp":"30 August 2010","dateIssuedKey":"2010"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"titleAlt":[{"title":"The NK 1 receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma"}],"person":[{"role":"aut","given":"Gerlinde","display":"Egerer, Gerlinde","family":"Egerer"},{"display":"Eisenlohr, Kathrin","role":"aut","given":"Kathrin","family":"Eisenlohr"},{"role":"aut","given":"Martina","display":"Gronkowski, Martina","family":"Gronkowski"},{"role":"aut","given":"Jürgen","display":"Burhenne, Jürgen","family":"Burhenne"},{"family":"Riedel","display":"Riedel, Klaus-Dieter","given":"Klaus-Dieter","role":"aut"},{"role":"aut","given":"Gerd","display":"Mikus, Gerd","family":"Mikus"}],"name":{"displayForm":["Gerlinde Egerer, Kathrin Eisenlohr, Martina Gronkowski, Juergen Burhenne, Klaus-Dieter Riedel & Gerd Mikus"]}} | ||
| SRT | |a EGERERGERLNK1RECEPTO3020 | ||